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Background: Wedelolactone (WEL), a major coumestan ingredient in Wedelia chinensis, has been used to treat septic
shock, hepatitis and venom poisoning in traditional Chinese medicines. The objective of the study was to elucidate
the anti-inflammatory effects and mechanism of WEL with a cellular model of lipopolysaccharide (LPS)-induced
RAW 264.7 cells.
Results: To study the role of WEL in pro-inflammation, we measured key inflammation mediators and end products
including nitric oxide (NO), prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2)
and tumor necrosis factor-α (TNF-α) by using the Griess method, enzyme linked immunosorbent assay (ELISA) and
Western blotting. Nuclear factor-kappaB (NF-κB) transcription activity was detected by luciferase reporter assay.
The important pro-inflammatory transcription factors, NF-κB p65 and inhibitory kappaB alpha (IκB-α); and
mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinase (ERK), c-Jun N-terminal
kinase (JNK) and p38 MAPK (p38) were analyzed by Western blotting. Our study showed that WEL (0.1, 1, 10 μM)
significantly inhibited the protein expression levels of iNOS and COX-2 in LPS-stimulated cells, as well as the
downstream products, including NO, PGE2 and TNF-α. Moreover, WEL also inhibited LPS-induced NF-κB p65
activation via the degradation and phosphorylation of IκB-α and subsequent translocation of the NF-κB p65 subunit
to the nucleus.
Conclusions: Our results revealed that WEL has a potential to be a novel anti-inflammatory agent targeting on
the NF-κB signaling pathway.
Keywords: Wedelolactone (WEL), Popolysaccharide (LPS), Inflammation, Nuclear factor-κB (NF-κB), MacrophageBackground
Wedelolactone (WEL), a common ingredient in Wedelia
chinensis and Eclipta prostrata, belongs to the flavonoids
category of phytoestrogens [1,2] (structure shown in
Figure 1). As a perennial herbal, WEL has been widely
used to treat septic shock, hepatitis and venom poisoning
in China [3-5]. Previous studies have shown that WEL
has diverse pharmacological effects such as antihepato-
toxic, antiandrogenic and anti-human immunodeficiency
activities [6-8]. Kobori M et al. demonstrated that WEL* Correspondence: gdpufredayuan@163.com
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reproduction in any medium, provided the orinhibits NF-kappaB (NF-κB) pathway by directly blocking
phosphorylation and degradation of inhibitory kappaB
alpha (IκBα) [9]. Based on this result, Ruhland A et al. re-
ported that WEL can reverse host cell resistance to
parasite-induced apoptosis by inhibiting NF-κB signaling
pathway [10]. Other results showed that WEL inhibits
adipogenesis via activation of the ERK pathway [1]. Both
WEL and demethyl-wedelolactone (DWL) showed tryp-
sin inhibition effects in vitro [11]. Taken together, WEL
has been identified as an anti-NF-κB translocation,
growth inhibitory and pro-apoptotic agent in differentiated
and cancer cells [1,6,9,10]. However, the precise mecha-
nisms of its anti-inflammation effects have not been com-
pletely delineated.
Inflammation is an important host response to foreign
challenge or tissue injury, which leads to the restorationd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Chemical structure of WEL.
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cess, the activation of immune cells induced by pro-
inflammatory cytokines up-regulates inflammation [13,14].
It is well known that macrophages, together with neutro-
phils and dendritic cells, play an important role in the
innate immune response [15]. The key inflammatory
mediators such as nitric oxide (NO), inducible nitric
oxide synthase (iNOS), prostaglandin E2 (PGE2) and
cyclooxygenase-2 (COX-2) and pro-inflammatory cytokine
such as tumor-necrosis factor α (TNF-α) can be released
by activated macrophages [16]. Lipopolysaccharide (LPS), a
cell wall component of Gram-negative bacteria, has been
reported to activate macrophages to produce inflammatory
mediators such as iNOS, TNF-α and COX-2, mimicking
the inflammatory reaction in vivo [14]. LPS triggers a serial
of signal transduction events which lead to the activation
of NF-κB and mitogen-activated protein kinase (MAPK)
signaling pathway [17]. Herein, LPS induced macrophages
is a well-established model for innate immunity study [18].
NF-κB has a pivotal role in immune and inflammatory re-
sponses through the regulation of pro-inflammatory cyto-
kines, adhesion molecules, chemokines, growth factors and
inducible enzymes, such as COX-2 and iNOS [12]. The ac-
tivation of NF-κB in response to pro-inflammatory stimuli
such as TNF-α has been characterized extensively. TNF-α
stimulates the phosphorylation, ubiquitylation and subse-
quent degradation of inhibitor of IκBα [12]. Mitogen-
activated protein kinases (MAPKs) play a key role in the
signaling pathways of cell proliferation, differentiation, sur-
vival, apoptosis and extracellular signal transduction to the
nucleus [19,20]. MAPKs can be activated by Toll-like re-
ceptor 4 (TLR4) leading to the activation of nuclear trans-
location of NF-κB and finally initiates pro-inflammatory
responses [21]. NF-κB is activated by phosphorylation
of IκBα via activation of MAPKs such as ERK1/2, JNK
and p38 subfamilies, and then migrates into the nucleus
and activates the expression of inflammatory cytokines
and mediators [12,19,22]. The activation of NF-κB in
response to pro-inflammatory stimuli such as TNF-α
through phosphorylation of IκBα results in the NF-κBp65–p50 heterodimer to migrate into the nucleus and
up-regulating the expression of pro-inflammatory and
anti-apoptotic genes [12].
In the present study, we investigated the anti-
inflammatory effects of WEL in LPS-stimulated RAW
264.7 cells and examined whether WEL could inhibit
inflammatory responses via suppression of the NF-κB
and MAPKs signaling pathways.
Methods
Cell culture and cell viability assay
Raw 264.7 cell line was obtained from cell bank, Insti-
tute of Biochemistry and Cell Biology (Shanghai, China).
Raw 264.7 cells were cultured in DMEM with 10% fetal
bovine serum, in an incubator at 37°C, 5% CO2 and 95%
humidity. The cyctotoxic effects of WEL were evaluated
in absence or presence of LPS by MTT assay. WEL was
dissolved in 10% dimethyl sulfoxide (DMSO) and added
directly to culture media before the addition of LPS. The
final concentration of DMSO never exceeded 0.1%.
Measurement of NO levels
The nitrite concentration in the culture medium was
measured by a Griess reaction test. Cells were plated as
a density of 2 × 106 cells/well in 24-well culture plates
and pretreated with or without indicated concentrations
of WEL (0.1, 1, 10 μM) or N-nitro-L-arginine methyl
ester (L-NAME) (100 μM) for 12 h, and then incubated
with LPS (1 μg/ml). 100 μM L-NAME, an inhibitor of
NO, was used as a positive control. After 20 h incubation,
cells were washed three times to remove non-adherent
cells. Then, 100 μl of the Griess reagent was mixed with
an equal volume of cell supernatant, the optical density at
540 nm was measured and the concentration of nitrite
was calculated according to the standard curve generated
from known concentrations of sodium nitrite.
Measurement of PGE2 levels
RAW 264.7 macrophages were subcultured in 24-well
plates and pretreated with or without indicated concen-
trations of WEL (0.1, 1, 10 μM) for 12 h or DX (0.1 μM)
for 1 h, then incubated with LPS (1 μg/ml) for 20 h. The
accumulated PGE2 in the culture medium was measured
using ELISA Kit (Cayman Chemical Company, Michigan,
USA) according to the manufacturer’s instructions. 0.1 μM
DX was used as a positive control.
Measurement of TNF-α levels
The effects of WEL on the production of TNF-α were
measured by ELISA. 2 × 106 RAW 264.7 cells (1% serum
starved) were seeded on 24-well plate at a density of 2 ×
106 per well for over-night. Cells were pre-incubated
with WEL (0.1, 1, 10 μM) or DX (0.1 μM) for 1 h, then
stimulated with 1 μg/ml LPS for another 20 h. The
Figure 2 Effects of WEL on the viability of RAW 264.7 cells. Cell
viability was measured by MTT assay. The values were presented as
mean ± SEM of three independent experiments, n = 6 per experiment.
*p < 0.05 vs. control group, **p < 0.01 vs. control group.
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the standard curve using recombinant cytokines in
each ELISA kits. All measurements above were performed
in triplicate.
Transient transfection and luciferase reporter assay
NF-κB reporter constructs were purchased from Clon-
tech Laboratories, Inc. (Palo Alto, CA, USA). For the
reporter assay, cells were seeded into 24-well plates at
a density of 5 × 105 cells per well in 500 μl of DMEM
without antibiotics and incubated overnight. The cells
in each well were transiently transfected with 200 ng
of luciferase reporter construct and 50 ng of internal
control plasmid of the pCMV-β-galactosidase reporter
plasmid or empty expression vector pcDNA3 using li-
pofectamine TM 2000 reagent according to the manu-
facturer’s procedures (Invitrogen, Carlsbad, CA, USA).
Six hours after transfection, the cells were washed with
phosphate-buffered saline to remove LiptofectamineTM
2000 complexes and then supplied with fresh medium
(supplemented with fetal calf serum and phenol red
free) and treated with WEL (0.1, 1 and 10 μM) for
12 h before stimulation with LPS (1 μg/ml) for 20 h.
Subsequently, luciferase activities were measured in
cell lysates using Dual Luciferase Reporter reagents fol-
lowing manufacturer’s instruction (Promega, Madison,
WI, USA).
Western blotting analysis
After treatment with various concentrations of WEL in
presence or absence of 1 μg/mL LPS, cells were analyzed
by immunoblotting. The treated cells were washed and
scraped into cold phosphate-buffered saline (PBS) and
centrifuged at 500 × g at 4°C. The cell pellets were resus-
pended in lysis buffer and centrifuged to yield whole-cell
lysates [23]. 20 μg protein for each sample was sepa-
rated by SDS-polyacrylamide gels with electrophoresis
(Bio-Rad, Hercules, CA, USA) and the gel was trans-
ferred to PVDF membrane. The membrane was blocked
with 10% skim milk for 1 h and then incubated overnight
at 4°C with 1:2000 dilution of the corresponding primary
antibody. After washing, the membranes were incu-
bated with the appropriate secondary antibody conju-
gated to horseradish peroxidase. The membrane was
immersed in the enhanced chemiluminescence solution
for 60 sec. The gel images were visualized using Chem-
Doc (Bio-Rad, Hercules, CA) and densitometric analysis
was performed with Quantity One 1-D Analysis software
(Bio-Rad). The results are representative of three inde-
pendent experiments.
Drugs and solutions
WEL (Purity ≥ 95%, by HPLC) (Xidian Pharmaceutical
Co., Ltd., Jilin, China) HEPES, LPS, N-nitro-L-argininemethyl ester and lipopolysaccharide (L-NAME) and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) (Sigma, St. Louis, MO, USA). Dulbecco’s modified
Eagle’s medium (DMEM) and bovine serum albumin
(BSA) (Gibco BRL, Gaithersburg, MD, USA). Griess re-
action kit for Nitric Oxide (NO) (Jiancheng Co., Ltd.,
Nanjing, China). ELISA kits for detecting TNF-α (R&D
Systems, Inc., USA). PGE2 ELISA Kit was obtained from
Cayman Chemical Company (Ann Arbor, MI, USA). Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA). Antibodies
specific for COX-2, iNOS, phospho-IκBα, NF-κBp65,
phospho-ERK1/2 and glyceraldehydes 3-phosphate de-
hydrogenase (GADPH) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA). Antibodies specific for MAPK
family proteins (ERK1/2, phospho-p38, p38, phospho-
JNK, JNK) (Cell Signaling Technology, Inc., Beverly, MA,
USA). All other reagents were of analytical grade.Statistical analysis
The results were expressed as mean ± standard error of
the mean (SEM) with the indicated number (n) of exper-
iments. Differences between groups for continuous vari-
ables were evaluated with analysis of variance (ANOVA)
and differences between two groups were analyzed using
unpaired Student’s t-test (SPSS version 10.0; Chicago, IL).
Statistical significance was set as p < 0.05.Results
Effects of WEL on cell viability
The cytotoxicity of WEL in RAW 264.7 cells was mea-
sured by MTT assay (Figure 2). The results showed that
WEL did not affect cell viability at a concentration of
0.1 μM to 100 μM regardless of the presence of LPS for
20 h. Therefore, a concentration of 0.1 to 10 μM of WEL
was used in all experiments.
AB
C
Figure 3 (See legend on next page.)
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Figure 3 Effects of WEL on LPS-induced NO, PGE2 and TNF-α production in RAW 264.7 macrophages. (A) Cells were treated with the
indicated concentrations of WEL (0, 0.1, 1, or 10 μ M) or 100 μM L-NAME for 12 h, respectively, and then incubated with LPS (1 μg/ml) for 20 h.
100 μM L-NAME group was set as positive control. The nitrite production was measured by the Griess reaction. (B, C) Cells were treated with the
indicated concentrations of WEL 12 h or 0.1 DX (0.1 μM) for 1 h, respectively, and then incubated with LPS (1 μg/ml) treatment for 20 h. The
PGE2 and TNF-α concentration were determined by ELISA kit. The values were presented as mean ± SEM. of three independent experiments.
n = 6 per experiment. *p < 0.05 vs. LPS group and **p < 0.01 vs. LPS group. #p < 0.05 vs. none LPS control group. ##p < 0.01 vs. none LPS
control group.
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LPS-stimulated cells
The potential anti-inflammatory effects of WEL on LPS-
stimulated NO and PGE2 production were examined in
RAW 264.7 macrophages by pretreating cells with vari-
ous concentrations of WEL for 12 h before stimulation
with 1 μg/mL LPS for 20 h. NO and PGE2 concentra-
tions in the culture medium were measured by Griess
reagent and ELISA, respectively. As shown in Figure 3,
NO and PGE2 production was remarkably induced
in LPS-stimulated RAW 264.7 macrophages whenFigure 4 Effects of WEL on iNOS and COX-2 protein expression in LPS
10 μ M) for 12 h, and then incubated with LPS (1 μg/ml) for 20 h. The tota
immunointensity between the iNOS, COX-2 and the GAPDH was calculated. A
analysis corresponding to the mean ± SEM. of three independent experiments
#p < 0.05 vs. none LPS control group. ##p < 0.01 vs. none LPS control group.compared with un-stimulated negative controls, while
pretreatment with WEL significantly prevented this in-
crease in a dose-dependent manner. This inhibitory ef-
fect was achieved with non-cytotoxic concentrations of
WEL.
Effects of WEL on TNF-α production in LPS-stimulated cells
To study the effects of WEL on LPS-induced inflammatory
related cytokine production, such as TNF-α production
in RAW 264.7 cells, cells were pretreated for 12 h
with various concentrations of WEL, followed by-induced cells. (A) Cells were pre-incubated with WEL (0, 0.1, 1, or
l protein lysate was subjected to Western blotting. (B) The ratio of
representative blot of each experiment is shown with the densitometric
. n = 6 per experiment. *p < 0.05 vs. LPS group and **p < 0.01 vs. LPS group.
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Figure 5 Effects of WEL on LPS-induced NF-κB transcriptional activity via suppression of IκB-α degradation and nuclear translocation
of the p65 and p50 subunits in RAW 264.7 cells. (A) Cells were transiently co-transfected with pNF-κB-Luc reporter plasmid and then were
pretreated with the indicated concentrations of WEL for 12 h. LPS (1 μg/ml) was then added and cells were further incubated for 20 h. The cells
were harvested and then the luciferase activities were determined by using the dual luciferase report assay system. (B, C) Cells were pretreated
with the indicated concentrations of WEL for12 h and then stimulated with LPS (1 μg/ml) treatment for 30 min. Cytosol (B) and nuclear (C) protein were
determined by Western blot assay using anti-IκB-α, NF-κB p50, and NF-κB p65. GAPDH and PARP1 were used as internal controls for Western blotting. A
representative blot of each experiment was shown with the densitometric analysis corresponding to the mean ± SEM. of three independent experiments.
n = 6 per experiment. *p < 0.05 vs. LPS group and **p < 0.01 vs. LPS group. #p < 0.05 vs. none LPS control group. ##p < 0.01 vs. none LPS control group.
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TNF-α induced by LPS was evaluated by ELISA. Our
result showed that WEL dose-dependently blocked
the expression of the pro-inflammatory cytokine TNF-α
(Figure 3).Effects of WEL on iNOS and COX-2 protein expression in
LPS-stimulated cells
Based on the findings above, we investigated whether
the inhibition of WEL on NO and PGE2 production was
related to down-regulation of iNOS and COX-2. Cells
were pretreated with the indicated concentration of WEL
for 12 h followed with LPS (1 μg/ml) treatment for
another 20 h. The protein levels of iNOS and COX-2
were significantly up-regulated in response to LPS, and
WEL inhibited the expression of these proteins in a dose-
dependent manner (Figure 4). These results showed that
WEL was able to inhibite the expression of iNOS and
COX-2 enzymes, which in turn reduce the production of
NO and PGE2, the two key mediators of inflammation,
respectively.Effects of WEL on LPS-mediated NF-κB transcriptional
activity via suppression of IκB-α degradation and nuclear
translocation of the p65 and p50 subunits in RAW 264.7 cells
NF-κB plays a pivotal role in regulation of the expression
of iNOS, COX-2 and inflammatory cytokines such as
TNF-α [12]. The heteromeric NF-κB complex is seques-
tered in the cytoplasm as an inactive precursor, com-
bined with an inhibitory IκB-α protein. Activation of
NF-κB, an important transcription factor in the inflam-
matory response, occurs after the phosphorylation,
ubiquitination and proteolytic degradation of IκB-α
[24]. To investigate the underlying mechanism of the
inhibition of WEL on iNOS and COX-2 protein ex-
pression in LPS-stimulated cells, luciferase reporter
assay was used to explore the effects of WEL on NF-
κB-dependent reporter gene expression following LPS
treatment. RAW 264.7 cells were transiently cotransfected
with a pNF-κB-leu reporter vector with four spaced NF-
κB-binding sites into the pLuc-promoter vector and then
stimulated with 1 μg/ml LPS with or without WEL. WEL
significantly reduced the level of NF-κB luciferase activityinduced by LPS in a dose-dependent manner (Figure 5A).
To further investigate whether WEL regulates the NF-κB
pathway, the cytoplasmic protein level of IκB-α was mea-
sured by western blotting after cells were pretreated
with the indicated concentrations of WEL for 12 h and
stimulated with LPS (1 μg/ml) for 30 min. The results
showed that WEL inhibited the phosphorylation and
degradation of the IκB-α protein after LPS treatment.
Because p65 and p50 are the major subunits of the
NF-κB heterodimer, the translocation of p65 and p50
subunits from the cytoplasm to the nucleus after being
released from IκB-α were investigated. As shown in
Figure 5B and C, the concentrations of p65 and p50 sub-
units were decreased in the cytoplasm and increased in
nucleus after LPS treatment, pretreatment with WEL re-
versed these trends in a dose-dependent manner. Taken
together, these findings demonstrated that WEL sup-
pressed the expression of iNOS and COX-2 at least in part
via NF-κB-dependent mechanism.Effects of WEL on the activation of ERK1/2, JNK and p38
in LPS-stimulated cells
Three MAPKs, ERK, p38 and JNK, are known to be ac-
tivated by LPS. MAPKs play an important role in the
transcriptional regulation of LPS-induced expression of
iNOS and COX-2 via activation of the transcription fac-
tor NF-κB [25]. Thus, we investigated the effect of
WEL on the activation of ERK1/2, JNK and p38. After
cells were pretreated with the indicated concentrations
of WEL for 12 h and stimulated with LPS (1 μg/ml) for
30 min, the expression of ERK1/2, JNK, and p38 was
analyzed by Western blotting. As shown in Figure 6,
WEL pretreatment obviously increased phosphorylation
of ERK1/2 (p-ERK1/2) and slightly enhanced phosphoryl-
ation of JNK (p-JNK). At the same time, WEL was
not observed to have any effect on the LPS-induced
phosphorylation of p38 MAPK. These results indicated
that the inhibitory effect of WEL on TNF-α, NO and
PGE2 was mediated possibly via the downstream MAPKs
pathway but independent of the activation of MAPKs.
NF-kB activation rather than the phophorylation of




Figure 6 (See legend on next page.)
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Figure 6 Effects of the WEL on the activation of ERK1/2 (A), JNK (B) and p38 (C) in LPS-stimulated cells. Cells were pre-incubated with
WEL for 12 h, and then incubated with LPS (1 μg/mL) for 30 min. The total protein lysate was subjected to Western blotting analysis. The ratios of
immunointensity of p-ERK1/2, p-JNK and p-p38 were calculated, respectively. Total ERK1/2, JNK and p38 (t-ERK1/2, t-JNK and t-p38) were used as a control
of the protein amount in the same samples. A representative blot of each experiment is shown with the densitometric anaylsis corresponding to the
mean ± SEM. of three independent experiments. n = 6 per experiment. *p < 0.05 vs. LPS group and **p< 0.01 vs. LPS group. #p< 0.05 vs. none LPS
control group. ##p < 0.01 vs. none LPS control group.
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WEL belongs to the flavonoids category of phytoestro-
gens in Eclipta prostrata and Wedelia chinensis. We in-
vestigated its anti-inflammatory activity and underlying
mechanism of WEL in LPS stimulated RAW 264.7 cells.
WEL has been identified as an anti-inflammatory, growth
inhibitory and pro-apoptotic agent in differentiated cells
and cancer cells [1,6,9,10]. Previous findings that WEL
inhibited IKK activity and caspase-11 expression which
resulted in the activation of NF-kB pathway suggested
that WEL could be a potential lead compound in anti-
inflammatory therapy [9]. However the mechanisms
of anti-inflammatory effects of WEL have not been
completely delineated. Thus, our study aimed to elucidate
the mechanisms underlying the anti-inflammatory effects
of WEL.
It is well-known that NO and PGE2 play critical roles in
the activation of macrophages, and they are closely associ-
ated with acute and chronic inflammation [12,26]. There-
fore, to study the suppression of NO and PGE2 by iNOS
and COX-2 is very important in the development of anti-
inflammatory agents [23,27]. Here, we demonstrated that
WEL can dose-dependently inhibit LPS-induced NO and
PGE2 production in RAW 264.7 macrophages. Consistent
with these findings, WEL also suppressed LPS-induced ex-
pression of iNOS and COX-2 at the protein levels in RAW
264.7 macrophages, which suggested that WEL-induced
reduction of NO and PGE2 may be due to transcriptional
suppression of iNOS and COX-2 genes. TNF-α plays a
critical role in innate immune responses and it is the prin-
cipal mediator in responses to LPS stimulated tissue injury
and shock. Therefore, we also investigated the effect of
WEL on LPS-inducible TNF-α expression [23]. Our results
showed that WEL significantly suppressed TNF-α produc-
tion in LPS-stimulated RAW 264.7 cells.
NF-κB plays a pivotal role in the regulation of the ex-
pression of iNOS, COX-2 and inflammatory cytokines
such as TNF-α [12]. Activation of NF-κB involves in the
phosphorylation and subsequent proteolytic degradation
of the inhibitory protein IκB by specific IκB kinases. The
free NF-κB (a heterodimer of p50 and p65) then passes
into the nucleus, where it binds to NF-κB site in the
promoter regions of genes for inflammatory proteins
such as cytokines, enzymes, and adhesion molecules
[24]. Therefore, we examined the effect of WEL on the
phosphorylation of IκB-α and the nuclear translocationof p65 and p50 subunits into the nucleus. Our results
showed that LPS treatment caused the decrease of p65
and p50 in the cytoplasm and increase in nucleus, and
this effect can be reversed by the pretreatment with
WEL in a dose-dependent manner. The present study
showed that WEL inhibited LPS-induced NF-κB acti-
vation through the suppression of the phosphorylation
and degradation of IκB-α and subsequent effects on
the nuclear translocation of the subunit of NF-κB in
RAW 264.7 macrophages.
The MAPKs pathway is one of the most ancient and
evolutionarily conserved signaling pathway and plays es-
sential regulatory roles in both innate and adaptive im-
mune response [17]. MAPKs play an important role in
the transcriptional regulation of LPS-induced expression
of iNOS and COX-2 [25]. LPS stimulation of cytokines
production in human monocytes is involved in several
intracellular signaling pathways that include three MAPK
pathways: ERK 1 and 2, JNK and p38 and IKK-NF-kB
pathway [25]. Several studies have shown that some active
compounds inhibit LPS-induced inflammatory cytokines
production via the down-regulation of NF-κB and MAPKs
activities in RAW 264.7 cells [20,26,28]. Thus, we investi-
gated the effect of WEL on activation of ERK1/2, JNK and
p38 in LPS-stimulated cells.
Our results showed that the phophorylation of JNK
and ERK in response to LPS were induced with WEL
treatment, whereas p38 phosphorylation was not affected.
These results indicated that anti-inflammatory mech-
anism of WEL was mediated possibly via the downstream
MAPKs pathway but independent of the activation of
MAPK signaling pathway. NF-kB activation rather than
the phophorylation of MAPKs may be involved in WEL
reduced cytokines production. Similar phenomena were
also found in the anti-inflammatory effect of Cucurbitacin
E, which was reported by Qiao J [29]. However, the role
and the underlying mechanism of WEL-induced activation
of MAPKs in LPS-stimulated cells are remained to be fur-
ther elucidated.
In conclusion, WEL was shown to inhibit the produc-
tion of NO and PGE2 as well as their upstream enzymes
iNOS and COX-2 at protein level through inhibition of
IκB-α phosphorylation and p65 nuclear translocation in
LPS-induced RAW 264.7 cells. The inhibition of iNOS
and COX-2 expression was mediated independent of the
MAPK.
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The results of our study indicated that WEL exerted
anti-inflammatory effects by suppressing the NF-κB path-
way. However, the effects of WEL on MAPKs pathway
need to be elucidated in further study.
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